# TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

> **NCT01294293** · PHASE1 · COMPLETED · sponsor: **Gynecologic Oncology Group** · enrollment: 20 (actual)

## Conditions studied

- Malignant Ovarian Mixed Epithelial Tumor
- Ovarian Brenner Tumor
- Ovarian Clear Cell Cystadenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Mucinous Cystadenocarcinoma
- Ovarian Serous Cystadenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Undifferentiated Ovarian Carcinoma

## Interventions

- **DRUG:** TLR8 Agonist VTX-2337
- **OTHER:** Diagnostic Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Pegylated Liposomal Doxorubicin Hydrochloride
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01294293
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2014-07
- **Final completion:** —
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-12-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01294293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01294293, "TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01294293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*